Advertisement
Advertisement

MXCT

MXCT logo

MaxCyte, Inc. Common Stock

1.14
USD
Sponsored
-0.02
-1.72%
Jun 16, 15:42 UTC -4
Closed
exchange

After-Market

1.14

0.00
0.00%

MXCT Earnings Reports

Positive Surprise Ratio

MXCT beat 17 of 20 last estimates.

85%

Next Report

Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$6.76M
/
-$0.09
Implied change from Q1 26 (Revenue/ EPS)
-29.93%
/
+125.00%
Implied change from Q2 25 (Revenue/ EPS)
-20.51%
/
-25.00%

MaxCyte, Inc. Common Stock earnings per share and revenue

On May 12, 2026, MXCT reported earnings of -0.04 USD per share (EPS) for Q1 26, beating the estimate of -0.08 USD, resulting in a 50.98% surprise. Revenue reached 9.65 million, compared to an expected 7.44 million, with a 29.64% difference. The market reacted with a +24.06% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.09 USD, with revenue projected to reach 6.76 million USD, implying an increase of 125.00% EPS, and decrease of -29.93% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Greenwich LifeSciences, Inc.
Report Date
Jun 04, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.39
Surprise
-15.86%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, MaxCyte, Inc. Common Stock reported EPS of -$0.04, beating estimates by 50.98%, and revenue of $9.65M, 29.64% above expectations.
The stock price moved up 24.06%, changed from $0.82 before the earnings release to $1.02 the day after.
The next earning report is scheduled for Aug 10, 2026.
Based on -- analysts, MaxCyte, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $6.76M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement